Medexus Pharmaceuticals
Logotype for Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals (MDP) investor relations material

Medexus Pharmaceuticals Q2 2027 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Medexus Pharmaceuticals Inc
Q2 2027 earnings summary12 Nov, 2026

Executive summary

  • Q2 FY2027 net revenue was $29.100M, up 17.6% YoY; Adjusted EBITDA was $5.1M, operating income $2.440M and net income $0.813M, versus a $0.315M loss.

  • Q2 revenue, Adjusted EBITDA, operating income and net income were quarterly records since fiscal Q4 2025.

  • GRAFAPEX achieved record quarterly product-level net revenue of $5.7M, with results described as in line with FY2027 expectations.

Financial highlights

  • H1 revenue was $57.685M, up 16.9% YoY; growth reflected GRAFAPEX, IXINITY and Rasuvo, partly offset by prior-year royalty revenue.

  • H1 Adjusted EBITDA increased 25.2% to $9.8M and operating income rose 104.5% to $4.554M, primarily reflecting GRAFAPEX operating leverage.

  • Q2 gross profit was $16.274M versus $13.786M YoY; SG&A was $13.3M, up 11.6%, mainly due to GRAFAPEX commercialization spending.

  • Q2 operating cash flow was $5.4M versus $3.3M YoY; H1 operating cash flow was $4.677M versus $7.256M, reflecting higher income taxes and other factors.

  • H1 net income was $1.357M versus $0.2M; H1 basic and diluted EPS were $0.04 versus $0.01.

Outlook and guidance

  • FY2027 GRAFAPEX product-level net revenue guidance remains $30M–$32M, requiring acceleration in the remainder of the year through expected adoption and repeat orders.

  • Long-term GRAFAPEX annual product-level net revenue target is $100M–$175M within five years of launch; long-term product-level Adjusted Gross Margin is expected to reach ~85%.

  • GRAFAPEX personnel and infrastructure spending is expected at $3M–$4M per quarter through FY2027; additional field-force resources began deployment in Q2.

  • Meaningful FY2027 operating cash flow is expected as GRAFAPEX scales; working capital may affect quarterly cash flow. Cash and expected operating cash flow are expected to cover operating and capital needs for at least 12 months.

  • UM171 Cell Therapy commercialization in Canada is not expected before calendar 2028, or potentially 2031 depending on regulatory pathways.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Medexus Pharmaceuticals earnings date

Logotype for Medexus Pharmaceuticals Inc
Q3 202711 Feb, 2027
Medexus Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Medexus Pharmaceuticals earnings date

Logotype for Medexus Pharmaceuticals Inc
Q3 202711 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the specialty areas of rheumatoid arthritis, asthma/allergy, psoriasis/dermatology, and gastrointestinal disorders through its sales and marketing activities and an expanding network of professional relationships. The company markets its products through sales representatives.